Published in Am J Respir Crit Care Med on July 06, 2006
Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2009) 2.68
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
The Microbiome and the Respiratory Tract. Annu Rev Physiol (2015) 1.35
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology (2011) 1.32
The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol (2010) 1.27
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J (2010) 1.26
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer (2011) 1.26
TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med (2010) 1.21
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol (2011) 1.21
Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol (2007) 1.13
The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One (2012) 1.07
MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med (2010) 1.06
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 1.04
Baseline 6-min walk distance predicts survival in lung transplant candidates. Am J Transplant (2008) 1.04
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Reproducibility of dynamically represented acoustic lung images from healthy individuals. Thorax (2007) 1.03
Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest (2009) 1.03
Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2008) 0.98
Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. Am J Respir Crit Care Med (2008) 0.92
miR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol (2014) 0.91
Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med (2013) 0.91
The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med (2009) 0.89
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest (2016) 0.86
Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med (2010) 0.86
The value of CT for disease detection and prognosis determination in combined pulmonary fibrosis and emphysema (CPFE). PLoS One (2014) 0.84
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.84
Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2011) 0.83
Severity classification for idiopathic pulmonary fibrosis by using fuzzy logic. Clinics (Sao Paulo) (2011) 0.83
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis (2014) 0.81
Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. J Oncol (2016) 0.80
Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung (2011) 0.80
Desaturation - distance ratio: a new concept for a functional assessment of interstitial lung diseases. Clinics (Sao Paulo) (2010) 0.80
Idiopathic Pulmonary Fibrosis: Adaptive Multiple Features Method Fibrosis Association with Outcomes. Am J Respir Crit Care Med (2016) 0.79
The Role of Cardiopulmonary Exercise Test in IPF Prognosis. Pulm Med (2013) 0.78
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis. Can Respir J (2014) 0.78
Heart rate response to a timed walk and cardiovascular outcomes in older adults: the cardiovascular health study. Cardiology (2012) 0.78
Cardiopulmonary exercise testing in lung transplantation: a review. Pulm Med (2012) 0.78
Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test. BMC Pulm Med (2014) 0.78
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One (2013) 0.77
Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes (2012) 0.77
Utility of the 6-minute walk test following lung transplantation. Ochsner J (2010) 0.76
Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax (2009) 0.76
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J (2011) 0.76
Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med (2014) 0.75
[(18)F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res (2017) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? BMC Pulm Med (2017) 0.75
Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis (2016) 0.75
Application of a new parameter in the 6-minute walk test for manifold analysis of exercise capacity in patients with COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.75
Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev (2016) 0.75
Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis. J Clin Med (2016) 0.75
Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease. Can Respir J (2016) 0.75
Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas (2016) 0.75
Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ (2016) 0.75
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight (2017) 0.75
Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res (2017) 0.75
Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol (2016) 0.75
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med (2017) 0.75
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med (2001) 4.45
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med (2001) 4.39
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax (2003) 2.54
Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med (1998) 2.43
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest (2003) 2.16
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med (2005) 1.86
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med (2005) 1.77
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest (2005) 1.60
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J (2005) 1.47
Pathophysiology of activity limitation in patients with interstitial lung disease. Chest (1996) 1.41
Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med (2001) 1.29
Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med (2005) 1.15
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol (2005) 1.09
Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax (2005) 1.03
Ventilation-perfusion matching during exercise. Chest (1992) 0.90
Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J (1988) 0.88
Ventilation-perfusion relationships in interstitial lung disease. Eur J Respir Dis (1986) 0.85
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology (2012) 6.92
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
The 2004 World Health Organization classification of lung tumors. Semin Roentgenol (2005) 5.23
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med (2010) 3.91
Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med (2003) 3.81
Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. AJR Am J Roentgenol (2009) 3.76
Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med (2007) 3.72
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology (2005) 3.71
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A (2012) 3.43
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med (2012) 3.42
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Lung image database consortium: developing a resource for the medical imaging research community. Radiology (2004) 3.19
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 2.95
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology (2007) 2.70
The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol (2006) 2.68
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med (2002) 2.56
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys (2011) 2.48
Radiation dose from cardiac computed tomography before and after implementation of radiation dose-reduction techniques. JAMA (2009) 2.48
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
US lung cancer trends by histologic type. Cancer (2014) 2.46
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst (2013) 2.45
International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol (2012) 2.45
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med (2009) 2.43
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35